Former Pfizer/Warner-Lambert VP-Global Marketing Gary Noon is appointed president-IMS Health North America. Noon is replacing Robert Hooper, who was promoted to senior VP-IMS Health. Noon will report to former IBM Senior VP David Thomas, who was named chairman & CEO of IMS the same day. Former Chairman Robert Weissman will aid in the transition as chair of the IMS Executive Committee. Former CEO Victoria Fash "will take a less active role in the company due to a chronic spinal condition which requires surgery and a lengthy convalescence"
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
New guidance from the National Pharmaceutical Regulatory Agency responds to the medicines shortages crisis that Malaysia experienced a few years ago.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.
